1
|
Chuong MD, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, Padgett KR, Zaki B, Zhang R, Kim H, Henke LE, Price AT, Mancias JD, Williams CL, Ng J, Pennell R, Raphael Pfeffer M, Levin D, Mueller AC, Mooney KE, Kelly P, Shah AP, Boldrini L, Placidi L, Fuss M, Jitendra Parikh P. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study. Radiother Oncol 2024; 191:110064. [PMID: 38135187 DOI: 10.1016/j.radonc.2023.110064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 12/03/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023]
Abstract
BACKGROUND AND PURPOSE Radiation dose escalation may improve local control (LC) and overall survival (OS) in select pancreatic ductal adenocarcinoma (PDAC) patients. We prospectively evaluated the safety and efficacy of ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC). The primary endpoint of acute grade ≥ 3 gastrointestinal (GI) toxicity definitely related to SMART was previously published with median follow-up (FU) 8.8 months from SMART. We now present more mature outcomes including OS and late toxicity. MATERIALS AND METHODS This prospective, multi-center, single-arm open-label phase 2 trial (NCT03621644) enrolled 136 patients (LAPC 56.6 %; BRPC 43.4 %) after ≥ 3 months of any chemotherapy without distant progression and CA19-9 ≤ 500 U/mL. SMART was delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions (biologically effective dose10 [BED10] = 100 Gy). Elective coverage was optional. Surgery and chemotherapy were permitted after SMART. RESULTS Mean age was 65.7 years (range, 36-85), induction FOLFIRINOX was common (81.7 %), most received elective coverage (57.4 %), and 34.6 % had surgery after SMART. Median FU was 22.9 months from diagnosis and 14.2 months from SMART, respectively. 2-year OS from diagnosis and SMART were 53.6 % and 40.5 %, respectively. Late grade ≥ 3 toxicity definitely, probably, or possibly attributed to SMART were observed in 0 %, 4.6 %, and 11.5 % patients, respectively. CONCLUSIONS Long-term outcomes from the phase 2 SMART trial demonstrate encouraging OS and limited severe toxicity. Additional prospective evaluation of this novel strategy is warranted.
Collapse
Affiliation(s)
- Michael D Chuong
- Miami Cancer Institute, Baptist Health South Florida, Miami, FL, United States.
| | - Percy Lee
- City of Hope National Medical Center, Los Angeles, CA, United States
| | - Daniel A Low
- UCLA Department of Radiation Oncology, Los Angeles, CA, United States
| | - Joshua Kim
- Henry Ford Health - Cancer, Detroit, MI, United States
| | - Kathryn E Mittauer
- Miami Cancer Institute, Baptist Health South Florida, Miami, FL, United States
| | - Michael F Bassetti
- University of Wisconsin-Madison, Department of Human Oncology, Madison, WI, United States
| | - Carri K Glide-Hurst
- University of Wisconsin-Madison, Department of Human Oncology, Madison, WI, United States
| | - Ann C Raldow
- Department of Radiation Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, United States
| | - Yingli Yang
- Department of Radiation Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, United States
| | - Lorraine Portelance
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL, United States
| | - Kyle R Padgett
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL, United States
| | - Bassem Zaki
- Section of Radiation Oncology Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States
| | - Rongxiao Zhang
- Section of Radiation Oncology Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States
| | - Hyun Kim
- Washington University School of Medicine in St. Louis, St. Louis, MO, United States
| | - Lauren E Henke
- Washington University School of Medicine in St. Louis, St. Louis, MO, United States
| | - Alex T Price
- Washington University School of Medicine in St. Louis, St. Louis, MO, United States
| | - Joseph D Mancias
- Brigham and Women's Hospital, Department of Radiation Oncology, Dana-Farber Cancer Institute, Department of Radiation Oncology, Harvard Medical School, Boston, MA, United States
| | - Christopher L Williams
- Brigham and Women's Hospital, Department of Radiation Oncology, Dana-Farber Cancer Institute, Department of Radiation Oncology, Harvard Medical School, Boston, MA, United States
| | - John Ng
- Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, NY, United States
| | - Ryan Pennell
- Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, NY, United States
| | | | - Daphne Levin
- Assuta Medical Center, Tel Aviv, IL, United States
| | - Adam C Mueller
- Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - Karen E Mooney
- Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States
| | - Patrick Kelly
- Orlando Health Cancer Institute, Orlando, FL, United States
| | - Amish P Shah
- Orlando Health Cancer Institute, Orlando, FL, United States
| | - Luca Boldrini
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Lorenzo Placidi
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | | | | |
Collapse
|
2
|
Parikh PJ, Lee P, Low DA, Kim J, Mittauer KE, Bassetti MF, Glide-Hurst CK, Raldow AC, Yang Y, Portelance L, Padgett KR, Zaki B, Zhang R, Kim H, Henke LE, Price AT, Mancias JD, Williams CL, Ng J, Pennell R, Pfeffer MR, Levin D, Mueller AC, Mooney KE, Kelly P, Shah AP, Boldrini L, Placidi L, Fuss M, Chuong MD. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2023; 117:799-808. [PMID: 37210048 DOI: 10.1016/j.ijrobp.2023.05.023] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 05/04/2023] [Accepted: 05/13/2023] [Indexed: 05/22/2023]
Abstract
PURPOSE Magnetic resonance (MR) image guidance may facilitate safe ultrahypofractionated radiation dose escalation for inoperable pancreatic ductal adenocarcinoma. We conducted a prospective study evaluating the safety of 5-fraction Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for locally advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). METHODS AND MATERIALS Patients with LAPC or BRPC were eligible for this multi-institutional, single-arm, phase 2 trial after ≥3 months of systemic therapy without evidence of distant progression. Fifty gray in 5 fractions was prescribed on a 0.35T MR-guided radiation delivery system. The primary endpoint was acute grade ≥3 gastrointestinal (GI) toxicity definitely attributed to SMART. RESULTS One hundred thirty-six patients (LAPC 56.6%, BRPC 43.4%) were enrolled between January 2019 and January 2022. Mean age was 65.7 (36-85) years. Head of pancreas lesions were most common (66.9%). Induction chemotherapy mostly consisted of (modified)FOLFIRINOX (65.4%) or gemcitabine/nab-paclitaxel (16.9%). Mean CA19-9 after induction chemotherapy and before SMART was 71.7 U/mL (0-468). On-table adaptive replanning was performed for 93.1% of all delivered fractions. Median follow-up from diagnosis and SMART was 16.4 and 8.8 months, respectively. The incidence of acute grade ≥3 GI toxicity possibly or probably attributed to SMART was 8.8%, including 2 postoperative deaths that were possibly related to SMART in patients who had surgery. There was no acute grade ≥3 GI toxicity definitely related to SMART. One-year overall survival from SMART was 65.0%. CONCLUSIONS The primary endpoint of this study was met with no acute grade ≥3 GI toxicity definitely attributed to ablative 5-fraction SMART. Although it is unclear whether SMART contributed to postoperative toxicity, we recommend caution when pursuing surgery, especially with vascular resection after SMART. Additional follow-up is ongoing to evaluate late toxicity, quality of life, and long-term efficacy.
Collapse
Affiliation(s)
| | - Percy Lee
- City of Hope National Medical Center, Los Angeles, California
| | - Daniel A Low
- Department of Radiation Oncology, University of California, Los Angeles, California
| | - Joshua Kim
- Henry Ford Health - Cancer, Detroit, Michigan
| | | | - Michael F Bassetti
- Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin
| | - Carri K Glide-Hurst
- Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin
| | - Ann C Raldow
- Department of Radiation Oncology, UCLA David Geffen School of Medicine, Los Angeles, California
| | - Yingli Yang
- Department of Radiation Oncology, UCLA David Geffen School of Medicine, Los Angeles, California
| | - Lorraine Portelance
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, Florida
| | - Kyle R Padgett
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, Florida
| | - Bassem Zaki
- Section of Radiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
| | - Rongxiao Zhang
- Section of Radiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
| | - Hyun Kim
- Washington University School of Medicine in St. Louis, St. Louis, Missouri
| | - Lauren E Henke
- Washington University School of Medicine in St. Louis, St. Louis, Missouri
| | - Alex T Price
- Washington University School of Medicine in St. Louis, St. Louis, Missouri
| | - Joseph D Mancias
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Christopher L Williams
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - John Ng
- Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, New York
| | - Ryan Pennell
- Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, New York
| | | | | | - Adam C Mueller
- Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Karen E Mooney
- Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | | | - Amish P Shah
- Orlando Health Cancer Institute, Orlando, Florida
| | - Luca Boldrini
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Lorenzo Placidi
- Department of Radiology, Radiation Oncology and Hematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | | | - Michael D Chuong
- Miami Cancer Institute, Baptist Health South Florida, Miami, Florida
| |
Collapse
|
3
|
Chapman D, Parikh PJ, Dolan JL, Cunningham JM, Czarnecki E, Elshaikh MA, Dragovic J, Movsas B, Feldman AM. Does Stereotactic Online Adaptive MRgRT to the Prostate Preclude the Need for Rectal Spacer. Int J Radiat Oncol Biol Phys 2023; 117:e370. [PMID: 37785264 DOI: 10.1016/j.ijrobp.2023.06.2469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Historical prospective trials have shown that hydrogel rectal spacers can be very effective at decreasing rectal wall dose, and in turn rectal toxicity, in patients undergoing curative intent fractionated courses of radiotherapy for prostate cancer. However, in the modern era of stereotactic online adaptive MR guided radiation (MRgRT), it's not yet determined if rectal spacers improve the potential daily need for plan adaptation. MATERIALS/METHODS A prospective database of MRgRT patients were queried for intact prostate cancer patients who received stereotactic online adaptive MR guided radiation. Patients were reviewed for the presence of a hydrogel rectal spacer present on the planning images. The number of adaptive fractions as well as the organs at risk out of tolerance were noted for each patient. Comparisons between number of fractions adapted as well as the number of fractions adapted for rectal constraints, were noted. For each case within this patient group that required plan adaptation, pre-specified dose constraints were finally met prior to treatment delivery. RESULTS A total of 27 patients were treated with stereotactic online adaptive MRgRT from 2020 to 2022. 8 patients had a hydrogel rectal spacer placed prior to treatment. Out of the 95 fractions delivered to non-hydrogel patients, 78 were adapted, with 52 for urethra, 31 for bladder, 5 for bladder neck, and 35 for rectum. Of the 40 fractions delivered to patients with a hydrogel spacer, 20 were adapted. The corresponding reasons for adaptation in this group were 14 times for the urethra, 19 times for the bladder, 8 times for the bladder neck, and 8 times for the rectum. It was common for multiple at-risk organs to require adaptation for a single fraction within both cohorts. Although the percentage of patients requiring adaptation for rectal constraints was greater in the non-hydrogel patients (36.8% vs. 20%), this was not found to be statistically significant; p value greater than 0.1. CONCLUSION The presence of a rectal spacer did not significantly reduce the need for online plan adaptation of the rectum for stereotactic online adaptive MRgRT. Furthermore, patients with a rectal spacer continued to often require adaptation to meet other prescription constraints. Further work is necessary to better select patients who would benefit from hydrogel spacers in the setting of online adaptive MRgRT. Additionally, longer follow-up of this patient population coupled with a larger patient cohort overall remains needed to increase the power of this analysis and to further explore the clinical outcomes of this patient group.
Collapse
Affiliation(s)
| | - P J Parikh
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - J L Dolan
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - J M Cunningham
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - E Czarnecki
- Henry Ford Hospital, Detroit, MI, United States
| | - M A Elshaikh
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - J Dragovic
- Henry Ford Cancer Institute, Detroit, MI
| | - B Movsas
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | | |
Collapse
|
4
|
Czarnecki E, Dolan JL, Cunningham JM, Chapman D, Elshaikh MA, Dragovic J, Parikh PJ, Movsas B, Feldman AM. Does a Dominant Intraprostatic Lesion Boost Require Daily Adaptation when Treated with Stereotactic Online Adaptive MR-Guided Therapy? Int J Radiat Oncol Biol Phys 2023; 117:e374-e375. [PMID: 37785274 DOI: 10.1016/j.ijrobp.2023.06.2479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Multiple trials have demonstrated a dose-response relationship for radiation therapy in the treatment of localized prostate cancer. Recent data has also demonstrated a benefit with whole gland stereotactic radiation therapy (SBRT) in conjunction with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL). SBRT with a DIL boost can often increase dose to nearby organs at risk such as the rectum and online adaptive MR guided radiation therapy (MGgRT) may offer a dosimetric and toxicity benefit. MATERIALS/METHODS A prospective database of MRgRT patients was queried for intact prostate cancer patients who received SBRT with a SIB to the DIL. The guideline for adaptation for coverage was to ensure the PTV-prostate coverage at 95% of prescribed dose was greater than 92% or by discretion of the treating physician. Adaptions for organs at risk were made to meet prescription constraints. The number of fractions requiring adaptation to meet organs at risk constraints and/or adequate coverage were reviewed. RESULTS A total of 26 patients were treated with SBRT with a DIL boost using stereotactic online adaptive MRgRT from 2020 to 2022. 10 of 26 patients were treated for re-irradiation of intact prostate. Out of the 130 fractions delivered, 107 fractions required adaptation (82.3%). 59 fractions were adapted for urethra (45.2%), 48 fractions were adapted for bladder (36.9%), 36 fractions were adapted for rectum (27.7%), 23 fractions were adapted for bladder neck (17.7%), and 19 fractions were adapted for coverage (14.6%). For 53 fractions (40.8 %), adaptation was required for more than one organ at risk. CONCLUSION A total of 82.3% of fractions required adaptation for patients treated with SBRT with a DIL boost using stereotactic online adaptive MRgRT. Adaptation occurred most frequently for urethral (45.2%), bladder (36.9%), and rectal constraints (27.7%). Further studies are needed to elucidate if daily adaptive online MRgRT translates to reduced patient toxicity and improved quality of life.
Collapse
Affiliation(s)
- E Czarnecki
- Henry Ford Hospital, Detroit, MI, United States
| | - J L Dolan
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - J M Cunningham
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | | | - M A Elshaikh
- Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI
| | - J Dragovic
- Henry Ford Cancer Institute, Detroit, MI
| | | | - B Movsas
- Henry Ford Hospital, Detroit, MI
| | | |
Collapse
|
5
|
Bertholet J, Wan H, Toftegaard J, Schmidt ML, Chotard F, Parikh PJ, Poulsen PR. Fully automatic segmentation of arbitrarily shaped fiducial markers in cone-beam CT projections. Phys Med Biol 2017; 62:1327-1341. [DOI: 10.1088/1361-6560/aa52f7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
6
|
Noel CE, Santanam L, Olsen JR, Baker KW, Parikh PJ. An automated method for adaptive radiation therapy for prostate cancer patients using continuous fiducial-based tracking. Phys Med Biol 2010; 55:65-82. [PMID: 19949260 DOI: 10.1088/0031-9155/55/1/005] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Electromagnetic tracking technology is primarily used for continuous prostate localization during radiotherapy, but offers potential value for evaluation of dosimetric coverage and adequacy of treatment for dynamic targets. We developed a highly automated method for daily computation of cumulative dosimetric effects of intra- and inter-fraction target motion for prostate cancer patients using fiducial-based electromagnetic tracking. A computer program utilizing real-time tracking data was written to (1) prospectively determine appropriate rotational/translational motion limits for patients treated with continuous isocenter localization; (2) retrospectively analyze dosimetric target coverage after daily treatment, and (3) visualize three-dimensional rotations and translations of the prostate with respect to the planned target volume and dose matrix. We present phantom testing and a patient case to validate and demonstrate the utility of this application. Gamma analysis of planar dose computed by our application demonstrated accuracy within 1%/1 mm. Dose computation of a patient treatment revealed high variation in minimum dose to the prostate (D(min)) over 40 fractions and a drop in the D(min) of approximately 8% between a 5 mm and a 3 mm PTV margin plan. The infrastructure has been created for patient-specific treatment evaluation using continuous tracking data. This application can be used to increase confidence in treatment delivery to targets influenced by motion.
Collapse
Affiliation(s)
- C E Noel
- Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, St Louis, MO 63110, USA
| | | | | | | | | |
Collapse
|
7
|
Chaudhari SR, Goddu SM, Rangaraj D, Pechenaya OL, Lu W, Kintzel E, Malinowski K, Parikh PJ, Bradley JD, Low DA. Dosimetric variances anticipated from breathing- induced tumor motion during tomotherapy treatment delivery. Phys Med Biol 2009; 54:2541-55. [PMID: 19349658 DOI: 10.1088/0031-9155/54/8/019] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
8
|
Patel KH, Shastri H, Patel RZ, Parikh PJ, Patel HR, Pathak KJ. Halofantrine in the treatment of falciparum malaria. Indian J Malariol 1995; 32:1-5. [PMID: 8549834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
50 patients (45 males + 5 females) suffering from acute uncomplicated attack of Plasmodium falciparum (Pf) malaria were treated with 1500 mg of halofantrine divided in three doses of 500 mg each given at an interval of 6 h. Results showed there were no primary treatment failures. Average Parasite Clearance Time (av. PCT) was 51.12 h and average Fever Clearance Time (av. FCT) was 31.25 h. Adverse Drug Reactions (ADR) were mild and self limiting. We conclude that halofantrine is a quite safe and effective new antimalarial agent in the treatment of Pf malaria cases.
Collapse
Affiliation(s)
- K H Patel
- Department of Medicine, Pathology, Medical College, Baroda, India
| | | | | | | | | | | |
Collapse
|